Abstract:Background The most common clinical outcome observed after treatment with immune checkpoint inhibitor antibodies is disease stabilization. Using vaccines to generate high levels of tumor antigen-specific T-helper 1 (Th1), we show that tumors not eradicated by vaccination demonstrate prolonged disease stabilization. We evaluated the mechanism by which type I T cells inhibit disease progression and potentially influence the subsequent clinical response to standard therapy in treatment refractory cancers. Methods We employed a meta-analysis of studies with tumor growth from four different vaccines in two different mammary cancer models. The T-cell subtype and cytokine essential for vaccine-induced tumor inhibition was determined by in vivo neutralization studies and immunohistochemistry. The role of interferon gamma (IFN-γ) in receptor tyrosine kinase and downstream signaling was determined by immunoblotting. The role of suppressor of cytokine signaling 1 (SOCS1) on IFN-γ signaling was evaluated on SOCS1-silenced cells with immunoblotting and immunoprecipitation. The effect of vaccination on growth factor receptor signaling pathways, performed in both luminal (TgMMTVneu) and basal (C3(1)-Tag) mammary cancer models treated with paclitaxel or an anti-HER2-neu monoclonal antibody were assessed via immunoblotting. Results Immunization with an epitope-based vaccine targeting a representative tumor antigen resulted in elevated tumor trafficking Tbet+CD4 T cells, decreased tumor proliferation and increased apoptosis compared with control vaccinated mice. The resulting disease stabilization was dependent on IFN-γ-secreting CD4 + T cells. In the presence of excess IFN-γ, SOCS1 became upregulated in tumor cells, bound insulin receptor, insulin like growth factor receptor 1 and epidermal growth factor receptor resulting in profound oncogenic signaling inhibition. Silencing SOCS1 restored growth factor receptor signaling and proliferation and prevented cell death. Similar signaling perturbations were detected in vaccinated mice developing antigen-specific Th1 cells. Vaccination synergized with standard therapies and restored disease sensitivity to treatment with both a neu-specific antibody and paclitaxel in TgMMTVneu and to paclitaxel in C3(1)-Tag. Combination of vaccination and chemotherapy or biological therapy was more effective than monotherapy alone in either model and resulted in complete resolution of disease in some individuals. Conclusions These data suggest the clinical activity of type I T cells extends beyond direct tumor killing and immune therapies designed to increase type I T cells and could be integrated into standard chemotherapy regimens to enhance therapeutic efficacy.

Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation

L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy

A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response

A reservoir of stem-like CD8 + T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways

Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Lymph Node and Tumor-Associated PD-L1+ Macrophages Antagonize Dendritic Cell Vaccines by Suppressing CD8+ T Cells

98O: Characterization of Tumor Infiltrating Lymphocytes in Resectable Early Stage Non-Small Cell Lung Cancer

Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment

Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node

Depletion of CD4+CD25high Regulatory T Cells from Tumor Infiltrating Lymphocytes Predominantly Induces Th1 Type Immune Response in Vivo Which Inhibits Tumor Growth in Adoptive Immunotherapy

Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling

High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination